Interleukin-20 antibody is a potential therapeutic agent for experimental arthritis

Arthritis and Rheumatism

Volumn 62, Issue 11, 2010, Pages 3311-3321

  Hsu, Yu Hsiang ^a   Chang, Ming Shi ^a  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 2; CYTOKINE ANTIBODY; ETANERCEPT; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 20; INTERLEUKIN 20 ANTIBODY; INTERLEUKIN 6; MATRIX METALLOPROTEINASE; OSTEOCLAST DIFFERENTIATION FACTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DENSITY; CELL ISOLATION; CHONDROPATHY; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE SEVERITY; DRUG TARGETING; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBROBLAST; FLOW CYTOMETRY; GENE CONTROL; IMMUNIZATION; MOUSE; NONHUMAN; OSTEOBLAST; PAW EDEMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOLOGY; RAT; REAL TIME POLYMERASE CHAIN REACTION; RHEUMATOID ARTHRITIS; SYNOVIUM; TH17 CELL;

ANALYSIS OF VARIANCE; ANIMALS; ANTIBODIES; ARTHRITIS, EXPERIMENTAL; CELL LINE; CELLS, CULTURED; ENZYME-LINKED IMMUNOSORBENT ASSAY; FIBROBLASTS; FLOW CYTOMETRY; IMMUNOGLOBULIN G; INTERLEUKIN-17; INTERLEUKINS; MATRIX METALLOPROTEINASES; MICE; OSTEOBLASTS; RANK LIGAND; RATS; RECEPTORS, TUMOR NECROSIS FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SEVERITY OF ILLNESS INDEX; SYNOVIAL MEMBRANE;

EID: 78249273302     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.27689     Document Type: Article

References (44)

1. Feldmann M, Brennan FM, Maini RN,. Rheumatoid arthritis. Cell 1996; 85: 307 - 10.
2. Feldmann M, Brennan FM, Williams RO, Cope AP, Gibbons DL, Katsikis PD, et al. Evaluation of the role of cytokines in autoimmune disease: the importance of TNFα in rheumatoid arthritis. Prog Growth Factor Res 1992; 4: 247 - 55.
3. Hsu YH, Li HH, Hsieh MY, Liu MF, Huang KY, Chin LS, et al. Function of interleukin-20 as a proinflammatory molecule in rheumatoid and experimental arthritis. Arthritis Rheum 2006; 54: 2722 - 33.
4. Brennan F, Beech J,. Update on cytokines in rheumatoid arthritis. Curr Opin Rheumatol 2007; 19: 296 - 301.
5. Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999; 397: 315 - 23.
6. Saidenberg Kermanac'h N, Bessis N, Cohen-Solal M, De Vernejoul MC, Boissier MC,. Osteoprotegerin and inflammation. Eur Cytokine Netw 2002; 13: 144 - 53.
7. Bresnihan B,. Preventing joint damage as the best measure of biologic drug therapy. J Rheumatol Suppl 2002; 65: 39 - 43.
8. Durie FH, Fava RA, Noelle RJ,. Collagen-induced arthritis as a model of rheumatoid arthritis. Clin Immunol Immunopathol 1994; 73: 11 - 8.
9. Lubberts E, van den Berg WB,. Cytokines in the pathogenesis of rheumatoid arthritis and collagen-induced arthritis. Adv Exp Med Biol 2003; 520: 194 - 202.
10. Luross JA, Williams NA,. The genetic and immunopathological processes underlying collagen-induced arthritis. Immunology 2001; 103: 407 - 16.
11. Kudo O, Fujikawa Y, Itonaga I, Sabokbar A, Torisu T, Athanasou NA,. Proinflammatory cytokine (TNFα/IL-1α) induction of human osteoclast formation. J Pathol 2002; 198: 220 - 7.
12. Romas E, Gillespie MT, Martin TJ,. Involvement of receptor activator of NF-B ligand and tumor necrosis factor-α in bone destruction in rheumatoid arthritis. Bone 2002; 30: 340 - 6.
13. Vasilopoulos Y, Gkretsi V, Armaka M, Aidinis V, Kollias G,. Actin cytoskeleton dynamics linked to synovial fibroblast activation as a novel pathogenic principle in TNF-driven arthritis. Ann Rheum Dis 2007; 66 Suppl 3: iii23 - 8.
14. Bradley JR,. TNF-mediated inflammatory disease. J Pathol 2008; 214: 149 - 60.
15. Pope RM,. Apoptosis as a therapeutic tool in rheumatoid arthritis. Nat Rev Immunol 2002; 2: 527 - 35.
16. Maini RN, Taylor PC,. Anti-cytokine therapy for rheumatoid arthritis. Annu Rev Med 2000; 51: 207 - 29.
17. Feldmann M, Brennan FM, Foxwell BM, Maini RN,. The role of TNFα and IL-1 in rheumatoid arthritis. Curr Dir Autoimmun 2001; 3: 188 - 99.
18. Saito H, Kojima T, Takahashi M, Horne WC, Baron R, Amagasa T, et al. A tumor necrosis factor receptor loop peptide mimic inhibits bone destruction to the same extent as anti-tumor necrosis factor monoclonal antibody in murine collagen-induced arthritis. Arthritis Rheum 2007; 56: 1164 - 74.
19. McInnes IB, Schett G,. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol 2007; 7: 429 - 42.
20. Lubberts E,. IL-17/Th17 targeting: on the road to prevent chronic destructive arthritis? Cytokine 2008; 41: 84 - 91.
21. Miossec P,. Interleukin-17 in rheumatoid arthritis: if T cells were to contribute to inflammation and destruction through synergy [review]. Arthritis Rheum 2003; 48: 594 - 601.
22. Kotake S, Udagawa N, Takahashi N, Matsuzaki K, Itoh K, Ishiyama S, et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest 1999; 103: 1345 - 52.
23. Hwang SY, Kim HY,. Expression of IL-17 homologs and their receptors in the synovial cells of rheumatoid arthritis patients. Mol Cells 2005; 19: 180 - 4.
24. Stamp LK, James MJ, Cleland LG,. Interleukin-17: the missing link between T-cell accumulation and effector cell actions in rheumatoid arthritis? Immunol Cell Biol 2004; 82: 1 - 9.
25. Commins S, Steinke JW, Borish L,. The extended IL-10 superfamily: IL-10, IL-19, IL-20, IL-22, IL-24, IL-26, IL-28, and IL-29. J Allergy Clin Immunol 2008; 121: 1108 - 11.
26. Blumberg H, Conklin D, Xu WF, Grossmann A, Brender T, Carollo S, et al. Interleukin 20: discovery, receptor identification, and role in epidermal function. Cell 2001; 104: 9 - 19.
27. Hsieh MY, Chen WY, Jiang MJ, Cheng BC, Huang TY, Chang MS,. Interleukin-20 promotes angiogenesis in a direct and indirect manner. Genes Immun 2006; 7: 234 - 42.
28. Li HH, Hsu YH, Wei CC, Lee PT, Chen WC, Chang MS,. Interleukin-20 induced cell death in renal epithelial cells and was associated with acute renal failure. Genes Immun 2008; 9: 395 - 404.
29. Li HH, Cheng HH, Sun KH, Wei CC, Li CF, Chen WC, et al. Interleukin-20 targets renal mesangial cells and is associated with lupus nephritis. Clin Immunol 2008; 129: 277 - 85.
30. Wei CC, Chen WY, Wang YC, Chen PJ, Lee JY, Wong TW, et al. Detection of IL-20 and its receptors on psoriatic skin. Clin Immunol 2005; 117: 65 - 72.
31. Tritsaris K, Myren M, Ditlev SB, Hubschmann MV, van der Blom I, Hansen AJ, et al. IL-20 is an arteriogenic cytokine that remodels collateral networks and improves functions of ischemic hind limbs. Proc Natl Acad Sci U S A 2007; 104: 15364 - 9.
32. Chen WY, Cheng BC, Jiang MJ, Hsieh MY, Chang MS,. IL-20 is expressed in atherosclerosis plaques and promotes atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2006; 26: 2090 - 5.
33. Wei CC, Li HH, Hsu YH, Hsing CH, Sung JM, Chang MS,. Interleukin-20 targets renal cells and is associated with chronic kidney disease. Biochem Biophys Res Commun 2008; 374: 448 - 53.
34. Parrish-Novak J, Xu W, Brender T, Yao L, Jones C, West J, et al. Interleukins 19, 20, and 24 signal through two distinct receptor complexes. Differences in receptor-ligand interactions mediate unique biological functions. J Biol Chem 2002; 277: 47517 - 23.
35. Mihara K, Almansa C, Smeets RL, Loomans EE, Dulos J, Vink PM, et al. A potent and selective p38 inhibitor protects against bone damage in murine collagen-induced arthritis: a comparison with neutralization of mouse TNFα. Br J Pharmacol 2008; 154: 153 - 64.
36. Chen WY, Chang MS,. IL-20 is regulated by hypoxia-inducible factor and up-regulated after experimental ischemic stroke. J Immunol 2009; 182: 5003 - 12.
37. Rannou F, Francois M, Corvol MT, Berenbaum F,. Cartilage breakdown in rheumatoid arthritis. Joint Bone Spine 2006; 73: 29 - 36.
38. Wada T, Nakashima T, Hiroshi N, Penninger JM,. RANKL-RANK signaling in osteoclastogenesis and bone disease. Trends Mol Med 2006; 12: 17 - 25.
39. Close DR,. Matrix metalloproteinase inhibitors in rheumatic diseases. Ann Rheum Dis 2001; 60 Suppl 3: iii62 - 7.
40. Takayanagi H,. Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat Rev Immunol 2007; 7: 292 - 304.
41. Sato K, Suematsu A, Okamoto K, Yamaguchi A, Morishita Y, Kadono Y, et al. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med 2006; 203: 2673 - 82.
42. Huang KY, Lin RM, Chen WY, Lee CL, Yan JJ, Chang MS,. IL-20 may contribute to the pathogenesis of human intervertebral disc herniation. Spine 2008; 33: 2034 - 40.
43. Abramson SB, Amin A,. Blocking the effects of IL-1 in rheumatoid arthritis protects bone and cartilage. Rheumatology (Oxford) 2002; 41: 972 - 80.
44. Takayanagi H,. Osteoimmunology and the effects of the immune system on bone. Nat Rev Rheumatol 2009; 5: 667 - 76.